The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127449201 12744920 1 I 20100415 20130201 20160915 20160915 EXP US-ROCHE-1186985 ROCHE 48.87 YR F Y 71.70000 KG 20160915 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127449201 12744920 1 PS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) LAST ADMINISTERED DOSE: 09/APR/2010 125085 10 MG/KG SOLUTION FOR INFUSION
127449201 12744920 2 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) 125085 1340 MG
127449201 12744920 3 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) 125085 689 MG
127449201 12744920 4 SS Bevacizumab BEVACIZUMAB 1 125085
127449201 12744920 5 SS Bevacizumab BEVACIZUMAB 1 125085
127449201 12744920 6 SS Bevacizumab BEVACIZUMAB 1 125085
127449201 12744920 7 SS Bevacizumab BEVACIZUMAB 1 125085
127449201 12744920 8 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) LAST ADMINISTERED DOSE:16/APR/2010 0 25 MG
127449201 12744920 9 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) 0 100 MG
127449201 12744920 10 SS TEMSIROLIMUS TEMSIROLIMUS 1 Intravenous (not otherwise specified) 0 50 MG
127449201 12744920 11 SS TEMSIROLIMUS TEMSIROLIMUS 1 0
127449201 12744920 12 SS TEMSIROLIMUS TEMSIROLIMUS 1 0
127449201 12744920 13 SS TEMSIROLIMUS TEMSIROLIMUS 1 0
127449201 12744920 14 SS TEMSIROLIMUS TEMSIROLIMUS 1 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127449201 12744920 1 Carcinoid tumour
127449201 12744920 2 Metastases to retroperitoneum
127449201 12744920 3 Metastases to pelvis
127449201 12744920 4 Metastases to peritoneum
127449201 12744920 5 Metastases to bone
127449201 12744920 6 Metastases to breast
127449201 12744920 7 Metastases to liver
127449201 12744920 8 Carcinoid tumour
127449201 12744920 9 Metastases to retroperitoneum
127449201 12744920 10 Metastases to pelvis
127449201 12744920 11 Metastases to peritoneum
127449201 12744920 12 Metastases to bone
127449201 12744920 13 Metastases to breast
127449201 12744920 14 Metastases to liver

Outcome of event

Event ID CASEID OUTC COD
127449201 12744920 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
127449201 12744920 Anaemia
127449201 12744920 Haemorrhoids
127449201 12744920 Hypokalaemia
127449201 12744920 Lower gastrointestinal haemorrhage
127449201 12744920 Musculoskeletal pain
127449201 12744920 Proctalgia
127449201 12744920 Upper gastrointestinal haemorrhage

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127449201 12744920 1 20100212 0
127449201 12744920 2 20100312 0
127449201 12744920 3 20100409 0
127449201 12744920 8 20100212 0
127449201 12744920 9 20100312 0
127449201 12744920 10 20100409 0